Ann: Trading Halt, page-4

and the answer is .......drum roll. Exactly what it has always been.....just enough to support further investigation. I told you so.
Results

Data presented is for Cohort 2, Part A and B (Cohort 1 presented at ESMO2017). Of the 8 patients treated with 800mg NOX66, 7 completed monotherapy (one withdrawal prior to dosing). No AEs related to NOX66 were reported. Following three cycles of combination with carboplatin AUC4, 1 patient reported partial response, 4 stable disease and 1 disease progression. No AEs related to NOX66 have been reported.
Conclusions

NOX66 at 800mg is well tolerated as monotherapy and in combination with low dose carboplatin. Efficacy signals support further investigation of NOX66 in combination with standard chemotherapy.

https://cslide.ctimeetingtech.com/tat2018/attendee/confcal/session/calendar/2018-03-05